Condition 1: Catheter infections in patients undergoing dialysis. Condition 2: End stage renal disease. Condition 3: Dependence on renal dialysis. Infection and inflammatory reaction due to other cardiac and vascular devices, implants and grafts End stage renal disease Infection and inflammatory reaction due to other cardiac and vascular devices, implants and grafts
Conditions
Interventions
Intervention 1: Control group: Heparin at a concentration of 1,000–5,000 units/mL will be instilled into the catheter lumen as a lock solution after each hemodialysis session. This regimen represents
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Dialysis patients aged 18 to 80 years Catheterization >14 days or prior catheter removal >3 months before trial enrollment. Hemodialysis > 2 sessions/ week
Exclusion criteria
Exclusion criteria: Antibiotic use within 14 days prior to enrollment. Active infection at the site of the catheter Immunodeficiency pregnant woman Breastfeeding Allergy to Citrate, Heparin and Taurolidine History of seizure Any disease with vasculopathy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of Catheter-Related Bloodstream Infections (CRBSIs). Timepoint: Every 14 days. Method of measurement: Blood culture and laboratory parameters. | — |
Secondary
| Measure | Time frame |
|---|---|
| White blood cell. Timepoint: Every 14 days. Method of measurement: Blood sample.;Temprature. Timepoint: Every 14 days. Method of measurement: Thermometer.;Heart rate. Timepoint: Every 14 days. Method of measurement: Heart monitoring.;C-reactive protein. Timepoint: Every 14 days. Method of measurement: Blood sample.;Procalcitonin. Timepoint: Every 14 days. Method of measurement: Blood sample. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public Contactkosar ojaghi
Shahid Beheshti University of Medical Sciences
Outcome results
None listed